Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

Recent studies suggest that BRAF(V600)-mutated melanomas in particular respond to dual anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) immune checkpoint inhibition (ICI). Here we identified an over-representation of interleukin (IL)-17–type 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Váraljai, Renáta, Zimmer, Lisa, Al-Matary, Yahya, Kaptein, Paulien, Albrecht, Lea J., Shannan, Batool, Brase, Jan C., Gusenleitner, Daniel, Amaral, Teresa, Wyss, Nina, Utikal, Jochen, Flatz, Lukas, Rambow, Florian, Reinhardt, Hans Christian, Dick, Jenny, Engel, Daniel R., Horn, Susanne, Ugurel, Selma, Sondermann, Wiebke, Livingstone, Elisabeth, Sucker, Antje, Paschen, Annette, Zhao, Fang, Placke, Jan M., Klose, Jasmin M., Fendler, Wolfgang P., Thommen, Daniela S., Helfrich, Iris, Schadendorf, Dirk, Roesch, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518254/
https://www.ncbi.nlm.nih.gov/pubmed/37525015
http://dx.doi.org/10.1038/s43018-023-00610-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518254/
https://www.ncbi.nlm.nih.gov/pubmed/37525015
http://dx.doi.org/10.1038/s43018-023-00610-2

Ejemplares similares